MA29384B1 - Acides nucleiques de liaison a la ghreline - Google Patents

Acides nucleiques de liaison a la ghreline

Info

Publication number
MA29384B1
MA29384B1 MA30282A MA30282A MA29384B1 MA 29384 B1 MA29384 B1 MA 29384B1 MA 30282 A MA30282 A MA 30282A MA 30282 A MA30282 A MA 30282A MA 29384 B1 MA29384 B1 MA 29384B1
Authority
MA
Morocco
Prior art keywords
nucleotide
box
suite
nucleotides
nucleic acids
Prior art date
Application number
MA30282A
Other languages
English (en)
Inventor
Florian Jarosch
Dirk Eulberg
Christian Maasch
Steffen Helmling
Sven Klussmann
Original Assignee
Noxxon Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxxon Pharma Ag filed Critical Noxxon Pharma Ag
Publication of MA29384B1 publication Critical patent/MA29384B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3183—Diol linkers, e.g. glycols or propanediols
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

LA PRÉSENTE INVENTION SE RAPPORTE À UN ACIDE NUCLÉIQUE SE LIANT DE PRÉFÉRENCE À LA GHRÉLINE, LEDIT ACIDE NUCLÉIQUE COMPORTANT UNE PREMIÈRE BOÎTE A DE SUITE NUCLÉOTIDIQUE ET UNE SECONDE BOITE B DE SUITE NUCLÉOTIDIQUE, LADITE PREMIÈRE BOÎTE A DE SUITE NUCLÉOTIDIQUE COMPRENANT ENVIRON 25 NUCLÉOTIDES CONSÉCUTIFS, LA SECONDE BOÎTE B DE SUITE NUCLÉOTIDIQUE COMPORTANT ENVIRON 6 À 8 NUCLÉOTIDES CONSÉCUTIFS, UNE SUITE 3'-TERMINALE DE NUCLÉOTIDES DE LA PREMIÈRE BOÎTE A DE SUITE NUCLÉOTIDIQUE S'HYBRIDANT AVEC LA SECONDE BOÎTE B DE SUITE NUCLÉOTIDIQUE, L'HYBRIDATION PERMETTANT LA FORMATION D'UNE PREMIÈRE STRUCTURE À DOUBLE BRIN ET CETTE PREMIÈRE STRUCTURE À DOUBLE BRIN COMPRENANT UN RENFLEMENT.
MA30282A 2005-04-08 2007-10-08 Acides nucleiques de liaison a la ghreline MA29384B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05007795 2005-04-08

Publications (1)

Publication Number Publication Date
MA29384B1 true MA29384B1 (fr) 2008-04-01

Family

ID=37087373

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30282A MA29384B1 (fr) 2005-04-08 2007-10-08 Acides nucleiques de liaison a la ghreline

Country Status (24)

Country Link
US (2) US8101734B2 (fr)
EP (1) EP1866412A2 (fr)
JP (2) JP5308813B2 (fr)
KR (1) KR20080009072A (fr)
CN (1) CN101189337B (fr)
AP (1) AP2007004189A0 (fr)
AR (1) AR052741A1 (fr)
AU (1) AU2006233647A1 (fr)
BR (1) BRPI0608180A2 (fr)
CA (1) CA2605377A1 (fr)
CR (1) CR9423A (fr)
DO (1) DOP2006000085A (fr)
EA (1) EA200701901A1 (fr)
GB (1) GB2439673A (fr)
GT (1) GT200600137A (fr)
IL (1) IL186085A0 (fr)
MA (1) MA29384B1 (fr)
MX (1) MX2007012419A (fr)
NL (2) NL1031538C2 (fr)
PE (1) PE20061358A1 (fr)
TN (1) TNSN07375A1 (fr)
TW (1) TW200718781A (fr)
UY (1) UY29460A1 (fr)
WO (1) WO2006108599A2 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1530635B1 (fr) * 2002-08-01 2011-06-15 Noxxon Pharma AG Acides nucleiques a liaison de ghreline
OA13282A (en) * 2003-11-10 2007-01-31 Noxxon Pharma Ag Nucleic acids specifically binding bioactive ghrelin.
UY29460A1 (es) 2005-04-08 2006-11-30 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
EP2274331B1 (fr) 2008-05-02 2013-11-06 Novartis AG Molécules de liaison à base de fibronectine améliorées et leurs utilisations
US8796216B2 (en) * 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
WO2011051327A2 (fr) 2009-10-30 2011-05-05 Novartis Ag Petites protéines à chaîne unique de type anticorps
WO2011051466A1 (fr) 2009-11-02 2011-05-05 Novartis Ag Molécules de liaison anti-idiotypiques à base de fibronectine et leurs utilisations
WO2011092233A1 (fr) 2010-01-29 2011-08-04 Novartis Ag Conjugaison de levures pour produire des combinaisons de liants à base de fibronectine à haute affinité
PL2726511T3 (pl) 2011-07-01 2019-12-31 Ngm Biopharmaceuticals, Inc. Kompozycje, zastosowania i sposoby leczenia zaburzeń oraz chorób metabolicznych
NZ630484A (en) 2012-11-28 2017-04-28 Ngm Biopharmaceuticals Inc Compositions and methods for treatment of metabolic disorders and diseases
EP2938740B1 (fr) 2012-12-27 2022-04-20 NGM Biopharmaceuticals, Inc. Peptides chimériques fgf19 pour l'utilisation dans le traitement de maladies de l'acide biliaire
CN106913865A (zh) 2013-04-18 2017-07-04 阿尔莫生物科技股份有限公司 使用白细胞介素‑10治疗疾病和病症的方法
EP3010527B1 (fr) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Méthode d'évaluation de l'identité et de la stabilité d'une protéine
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
RU2016122957A (ru) 2013-11-11 2017-12-19 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
WO2015077717A1 (fr) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions et méthodes pour diagnostiquer, évaluer et traiter un cancer au moyen d'un état de méthylation d'adn
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3082853A2 (fr) 2013-12-20 2016-10-26 The Broad Institute, Inc. Polythérapie comprenant un vaccin à base de néoantigènes
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2015187295A2 (fr) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Méthodes permettant de faire baisser le cholestérol sérique
AU2015333827A1 (en) 2014-10-14 2017-04-20 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
KR20170084033A (ko) 2014-10-22 2017-07-19 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위해 인터루킨-10을 사용하는 방법
IL251834B2 (en) 2014-10-23 2023-09-01 Ngm Biopharmaceuticals Inc Pharmaceutical compositions containing peptide variants and methods of using them
EP3234193B1 (fr) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Biomarqueurs moléculaires pour l'immunothérapie d'un cancer
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
WO2016126615A1 (fr) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
EP3297660A2 (fr) 2015-05-20 2018-03-28 The Broad Institute Inc. Néo-antigènes partagés
WO2016191587A1 (fr) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Interleukine 10 pégylée utilisée pour le traitement du cancer
WO2017035232A1 (fr) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
ES2871036T3 (es) 2015-11-09 2021-10-28 Ngm Biopharmaceuticals Inc Método para el tratamiento de trastornos relacionados con ácidos biliares
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
HUE065174T2 (hu) 2017-02-12 2024-05-28 Biontech Us Inc HLA-alapú módszerek és készítmények, valamint azok felhasználása
US20200353050A1 (en) 2017-11-10 2020-11-12 Armo Biosciences, Inc. Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors
WO2019126186A1 (fr) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Néo-antigènes et leurs utilisations
CN112533629A (zh) 2018-06-19 2021-03-19 阿尔莫生物科技股份有限公司 结合使用il-10药剂与嵌合抗原受体细胞疗法的组合物和方法
WO2020072700A1 (fr) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Lignées d'allèles uniques d'alh
ES2957683T3 (es) 2018-10-24 2024-01-24 Hoffmann La Roche Procedimiento para la purificación de oligonucleótidos
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
SG11202106678PA (en) 2018-12-21 2021-07-29 Biontech Us Inc Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
EP3984595A4 (fr) * 2019-06-11 2023-08-16 Ajinomoto Co., Inc. Peptide et son utilisation
BR112021025050A2 (pt) 2019-06-12 2022-05-03 Biontech Us Inc Composições de neoantígeno e usos das mesmas
AU2021400424A1 (en) 2020-12-14 2023-07-06 Biontech Us Inc. Tissue-specific antigens for cancer immunotherapy
WO2024077256A1 (fr) 2022-10-07 2024-04-11 The General Hospital Corporation Procédés et compositions pour la découverte à haut débit de protéines de liaison ciblant un peptide-cmh

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614395A (en) * 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
ATE318832T1 (de) * 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
EP0825997A1 (fr) 1995-05-03 1998-03-04 Whitehead Institute For Biomedical Research Identification de ligands enantiomeres
DE19808591C2 (de) 1998-02-28 2000-02-03 Univ Leipzig Standardisierter durchflußzytometrischer Vollblutassay
EP1286697A2 (fr) 2000-05-17 2003-03-05 Eli Lilly And Company Procede d'inhibition selective de la ghreline
US20030211967A1 (en) * 2001-05-07 2003-11-13 Bryant Henry Uhlman Method for selectively inhibiting ghrelin action
US6967237B2 (en) 2000-05-30 2005-11-22 Merck & Co., Inc. Ghrelin analogs
US7629456B2 (en) * 2001-10-26 2009-12-08 Noxxon Pharma Ag Modified L-nucleic acid
EP1530635B1 (fr) * 2002-08-01 2011-06-15 Noxxon Pharma AG Acides nucleiques a liaison de ghreline
OA13282A (en) 2003-11-10 2007-01-31 Noxxon Pharma Ag Nucleic acids specifically binding bioactive ghrelin.
UY29460A1 (es) 2005-04-08 2006-11-30 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin

Also Published As

Publication number Publication date
US20060258607A1 (en) 2006-11-16
CA2605377A1 (fr) 2006-10-19
IL186085A0 (en) 2008-01-20
CN101189337B (zh) 2013-11-06
NL1033520C2 (nl) 2010-01-21
KR20080009072A (ko) 2008-01-24
PE20061358A1 (es) 2007-01-13
CN101189337A (zh) 2008-05-28
EA200701901A1 (ru) 2008-04-28
AU2006233647A2 (en) 2008-04-17
AP2007004189A0 (en) 2007-10-31
DOP2006000085A (es) 2006-11-15
UY29460A1 (es) 2006-11-30
GB0719489D0 (en) 2007-11-21
WO2006108599A2 (fr) 2006-10-19
JP5308813B2 (ja) 2013-10-09
GB2439673A (en) 2008-01-02
AR052741A1 (es) 2007-03-28
NL1031538C2 (nl) 2007-03-20
EP1866412A2 (fr) 2007-12-19
NL1031538A1 (nl) 2006-10-10
GT200600137A (es) 2006-11-22
AU2006233647A1 (en) 2006-10-19
BRPI0608180A2 (pt) 2009-11-17
MX2007012419A (es) 2007-12-05
US20120115937A1 (en) 2012-05-10
TW200718781A (en) 2007-05-16
WO2006108599A3 (fr) 2007-02-15
JP2013176372A (ja) 2013-09-09
CR9423A (es) 2007-12-17
US8101734B2 (en) 2012-01-24
TNSN07375A1 (fr) 2009-03-17
NL1033520A1 (nl) 2007-08-06
JP2008534024A (ja) 2008-08-28

Similar Documents

Publication Publication Date Title
MA29384B1 (fr) Acides nucleiques de liaison a la ghreline
WO2002038806A3 (fr) Identification de polymorphismes d'acide nucleique
EP2474631A3 (fr) Polymorphismes génétiques associés à l'infarctus du myocarde, procédés de détection et utilisations associées
WO2008079374A3 (fr) Procédés et compositions pour sélectionner et utiliser des polymorphismes d'un nucléotide simple
EP2329838A3 (fr) Nétrine 4 mutée, ses fragments et leur utilisation comme médicaments
EP2363416A3 (fr) Anticorps monoclonal dirigé contre la glycoprotéine VI plaquettaire
WO2006086669A8 (fr) Acides nucleiques regules par des aptameres et leurs utilisations
MX2009000654A (es) Medios para inhibir la expresion de la cinasa de proteina 3.
WO2008008553A3 (fr) Polymorphismes génétiques associés à la maladie d'alzheimer, leurs méthodes de détection et leurs applications
WO2007050705A3 (fr) Polymorphismes genetiques associes a la maladie d'alzheimer, ainsi leurs methodes de detection et d'utilisation
ATE446385T1 (de) Polymorphismen im nod2/card15 gen
WO2006046072A3 (fr) Proteines renfermant vwfa et/ou le domaine ant_ig
WO2009044085A3 (fr) Oligonucleotides, utilisation, methode de detection et kit permettant de diganostiquer la presence du gene e1 du virus de chikungunya
MX2007004271A (es) Enzimas involucradas en la sintesis de triterpenos.
WO2002103014A3 (fr) Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires
WO2008015380A3 (fr) Protéine membranaire intégrale
WO2006043060A3 (fr) Proteine contenant le domaine mam
WO2001066752A3 (fr) Genes specifiques de la reproduction
WO2007121946A3 (fr) Moyens pour inhiber l'expression de cd31
WO2002070559A3 (fr) Domaines de liaison des ligands des récepteurs d'hormones nucléaires
WO2005018431A3 (fr) Compositions et methodes servant a detecter et a traiter des affections neurologiques
WO2004101618A3 (fr) Proteines associees au recepteur de progestine yol002c-cgi-45
WO2007068913A3 (fr) Protéines contenant le domaine SRCR-B
WO2004089285A3 (fr) Phosphodiesterase 2a et leurs procedes d'utilisation
WO2002064743A3 (fr) Confirmation du contenu d'exon de transcrits d'arn par pcr au moyen d'amorces complementaires a chaque exon